Education
About Us
Working with TipRanks
Follow Us
Jacobson Pharma Corporation Limited (HK:2633)
:2633
2633 Stock Chart & Stats
HK$1.29
HK$0.01(0.99%)
At close: 4:00 PM EST
HK$1.29
HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.98 - HK$1.78
Previous CloseN/A
Volume1.98M
Average Volume (3M)821.71K
Market Cap
HK$2.41B
Enterprise ValueHK$3.03B
Total Cash (Recent Filing)HK$395.06M
Total Debt (Recent Filing)HK$904.62M
Price to Earnings (P/E)8.4
Beta0.07
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield15.4%
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,000,221,000
10 Day Avg. Volume1,775,382
30 Day Avg. Volume821,706
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.96
Price to Sales (P/S)1.49
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Operating Cash GenerationConsistently strong operating and free cash flow gives Jacobson durable financial flexibility: supports R&D, manufacturing investment, dividends and optional acquisitions without heavy reliance on external financing, and cushions the business against cyclical shocks over months to years.
Healthy Profit MarginsSustained gross and net margin strength implies durable pricing power and efficient cost controls across manufacturing and distribution. Solid operating margins provide long-term capacity to fund commercial expansion and absorb input-cost shocks while preserving cash generation.
Diversified Healthcare Revenue StreamsA multi-channel business model—branded/generic prescription sales, OTC, distribution and contract manufacturing—reduces single-product dependence, smooths cash flow across cycles, and leverages sales network and licensing relationships for durable revenue resilience.
Bears Say
Revenue SoftnessA decline in reported revenue signals potential demand pressure, product mix shifts, or timing of registrations. If persistent, revenue softness can constrain reinvestment, slow portfolio expansion and weaken long-term growth prospects absent new approvals or market share gains.
Moderate LeverageModerate leverage reduces balance-sheet flexibility for sizeable M&A, large capital projects or to withstand sustained downturns. Rising rates or margin pressure could increase interest burdens and limit strategic optionality, affecting long-term investment capacity.
Geographic Concentration RiskHeavy reliance on the Hong Kong healthcare market concentrates regulatory, reimbursement and demand risk. Regional policy shifts or slower local demand would materially affect sales growth and limit diversification benefits versus peers with broader geographic exposure.
Jacobson Pharma Corporation Limited News
2633 FAQ
What was Jacobson Pharma Corporation Limited’s price range in the past 12 months?
Jacobson Pharma Corporation Limited lowest stock price was HK$0.98 and its highest was HK$1.78 in the past 12 months.
What is Jacobson Pharma Corporation Limited’s market cap?
Jacobson Pharma Corporation Limited’s market cap is HK$2.41B.
When is Jacobson Pharma Corporation Limited’s upcoming earnings report date?
Jacobson Pharma Corporation Limited’s upcoming earnings report date is Jul 01, 2026 which is in 128 days.
How were Jacobson Pharma Corporation Limited’s earnings last quarter?
Jacobson Pharma Corporation Limited released its earnings results on Nov 18, 2025. The company reported HK$0.071 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.071.
Is Jacobson Pharma Corporation Limited overvalued?
According to Wall Street analysts Jacobson Pharma Corporation Limited’s price is currently Overvalued.
Does Jacobson Pharma Corporation Limited pay dividends?
Jacobson Pharma Corporation Limited pays a Semiannually dividend of HK$0.043 which represents an annual dividend yield of 15.4%. See more information on Jacobson Pharma Corporation Limited dividends here
What is Jacobson Pharma Corporation Limited’s EPS estimate?
Jacobson Pharma Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jacobson Pharma Corporation Limited have?
Jacobson Pharma Corporation Limited has 2,000,221,000 shares outstanding.
What happened to Jacobson Pharma Corporation Limited’s price movement after its last earnings report?
Jacobson Pharma Corporation Limited reported an EPS of HK$0.071 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.418%.
Which hedge fund is a major shareholder of Jacobson Pharma Corporation Limited?
Currently, no hedge funds are holding shares in HK:2633
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobson Pharma Corporation Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.83%
12-Months-Change
Fundamentals
Return on Equity
12.97%
Trailing 12-Months
Asset Growth
-2.19%
Trailing 12-Months
Company Description
Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited, through its subsidiaries, produces, markets, and sells generic drugs and branded healthcare products in Hong Kong, Mainland China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including the respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergics, scar treatment, oral anti-diabetics, and anti-infective, as well as arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. In addition, it engages in the trading of medical supplies; procurement of packaging materials; sale of healthcare and herbal products; research and development; and property holding activities. Jacobson Pharma Corporation Limited sells its products to hospitals and clinics, and registered pharmacies, as well as to doctors in private and retail outlets, and trading companies. The company was incorporated in 2016 and is headquartered in Kwun Tong, Hong Kong. Jacobson Pharma Corporation Limited is a subsidiary of Kingshill Development Limited.
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
JBM (Healthcare) Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
China Shineway Pharmaceutical Group Limited
―
Golden Throat Holdings Group Co Ltd
―
Options Prices
Currently, No data available
---